Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

382
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

357
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
357
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

379
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379
Hepatitis01:25

Hepatitis

81
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
81
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

46
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic...
46

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatic giant cells in hepatitis C virus (HCV) mono-infection and HCV/HIV co-infection.

Journal of clinical pathologyยท2008
Same author

Assessment of the morphology and significance of the lymph nodal and hepatic lesions produced in rats by the feeding of certain mineral oils and waxes. Proceedings of a pathology workshop held at the Fraunhofer Institute of Toxicology and Aerosol Research Hannover, Germany, May 7-9, 2001.

Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologieยท2001
Same author

Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine.

Hepatology (Baltimore, Md.)ยท2001
Same author

Comparison of a triple antigen and a single antigen recombinant vaccine for adult hepatitis B vaccination.

Journal of medical virologyยท2001
Same author

A multi-center controlled study of rapid hepatitis B vaccination using a novel triple antigen recombinant vaccine.

Vaccineยท2001
Same author

The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib.

American journal of therapeuticsยท2001
Same journal

How important is fiber in the Crohn's disease story?

Gastroenterologyยท2026
Same journal

Reply to "Critical Appraisal of the Integrin ฮฑV-YAP-CTGF Axis in Congestive Hepatopathy".

Gastroenterologyยท2026
Same journal

Critical Appraisal of the Integrin ฮฑV-YAP-CTGF Axis in Congestive Hepatopathy.

Gastroenterologyยท2026
Same journal

A High-Risk Impaction: To Scope or to Stent First?

Gastroenterologyยท2026
Same journal

Epithelial FOXP3 orchestrates O-glycosylated IL-6 secretion to drive pancreatic fibrocarcinogenesis.

Gastroenterologyยท2026
Same journal

Reply to "Methodological Considerations on Neonatal Metabolomics and Future Inflammatory Bowel Disease".

Gastroenterologyยท2026
See all related articles

Related Experiment Video

Updated: Apr 30, 2026

The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat
09:27

The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat

Published on: June 17, 2016

11.8K

Severe hepatitis from methyldopa.

W C Maddrey, J K Boitnott

    Gastroenterology
    |May 4, 2012
    PubMed
    Summary
    This summary is machine-generated.

    Methyldopa, a hypertension drug, can cause severe hepatitis. Discontinuing methyldopa rapidly improves liver health, even in cases mimicking chronic hepatitis.

    More Related Videos

    Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
    11:36

    Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

    Published on: May 29, 2020

    2.5K
    Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
    11:06

    Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

    Published on: January 31, 2022

    7.6K

    Related Experiment Videos

    Last Updated: Apr 30, 2026

    The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat
    09:27

    The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat

    Published on: June 17, 2016

    11.8K
    Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
    11:36

    Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

    Published on: May 29, 2020

    2.5K
    Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
    11:06

    Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

    Published on: January 31, 2022

    7.6K

    Area of Science:

    • Hepatology
    • Clinical Pharmacology

    Background:

    • Hypertension management often involves medications like methyldopa.
    • Drug-induced liver injury (DILI) is a significant clinical concern.
    • Methyldopa has been associated with various adverse effects, including hepatotoxicity.

    Observation:

    • Six cases of severe hepatitis linked to methyldopa therapy were observed over two years.
    • One patient experienced recurrent hepatitis upon inadvertent drug re-administration.
    • A fatal outcome occurred in one patient due to massive hepatic necrosis.

    Findings:

    • Liver biopsies in survivors showed severe hepatitis, histologically similar to early chronic aggressive hepatitis.
    • Discontinuation of methyldopa led to rapid and complete recovery in all affected patients.
    • The study highlights the potential for methyldopa to cause severe, potentially fatal, liver injury.

    Implications:

    • Clinicians should consider methyldopa as a potential cause of hepatitis in patients on this medication.
    • Prompt drug cessation is crucial upon detecting constitutional symptoms or biochemical evidence of hepatitis.
    • Investigating methyldopa's role is essential in patients presenting with histological patterns suggestive of chronic aggressive hepatitis.